Bernard Coulie, Pliant Therapeutics CEO
Pliant touts additional Phase 2a data for oral IPF drug that’s already in a pivotal study
Pliant Therapeutics unveiled more efficacy data from a small mid-stage trial of its lead candidate in idiopathic pulmonary fibrosis, which shows that its oral drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.